Here are five things to note:
1. The case study considered ambulation ability impact and quality of life measurements.
2. After six months of use, the patient could walk independently, and experienced improvements in mobility, falling risks, motor skills and bladder control.
3. ReWalk is CE marked and FDA cleared.
4. The study called for additional studies with more patients.
5. “The ReWalk system on the one hand creates an additional possibility of mobility for the patient, but is moreover also an excellent therapy and training tool for people with complete or incomplete paraplegia,” said Professor Dr. med. Karsten Krakow.
More articles on devices:
5 of Medtech’s biggest deals of 2015
Thuasne Group acquires Quinn Medical — 5 takeaways
7 new device launches & releases — January 26, 2015
